Roche Global CEO: helping Shanghai to build an Asian medical center city with international influence

October 28, 2018 / Meitong news agency / -- today, Dr Severin Schwan, Global CEO of Roche Group, attended the 30th Shanghai mayor's international entrepreneurship consultation conference (iblac), and delivered a keynote speech entitled "building an Asian medical center city with international influence, setting a brand benchmark for comprehensively deepening reform and opening up in Shanghai", to build a brand with high quality Asia Medical Center City, with the core of medical service and biomedical industry cluster, will become the core driving force of Shanghai brand This year, it is the 30th anniversary of Shanghai mayor's international entrepreneur consultation conference and the ninth consecutive year of Dr Shi Wan's participation in Shanghai, which demonstrates Roche's firm determination to promote the development of Shanghai and its long-term commitment to the Chinese market At this conference, Dr Shi Wan proposed that Shanghai should give full play to its own advantages, establish a special disease diagnosis and treatment center in the near future, develop the top biomedical industry in the long term, and support the construction of Asian medical center cities Shanghai should speed up the construction of a special disease diagnosis and treatment center with the characteristics of rare diseases and cancer diagnosis and treatment guided by policies Meanwhile, Shanghai should further deepen international cooperation in related fields and actively expand the clinical application of Internet plus technology based on artificial intelligence and big data In the long run, Shanghai can give full play to its advantages in resource allocation as an international financial center, and build a booming biomedical industry cluster covering "cutting-edge research and development" and "high-end manufacturing" in combination with continuous policy and institutional innovation, so as to provide long-term support for the construction of Asian Medical Center Cities Specifically, Shanghai should strive to improve the efficient interaction between industry, University, research and medicine within the cluster, accelerate the benchmarking to the best international level, and ensure the supply of advantageous industrial policies In addition, Shanghai can increase long-term investment in the biomedical industry through multi-level and multi-channel capital support and in-depth public-private cooperation, and vigorously attract and cultivate professionals in related fields In the past 40 years of reform and opening up, Shanghai has been an important engine of China's economic development and a gateway to opening up, and the Shanghai mayor's international entrepreneur consultation conference has witnessed the reform process of Shanghai As one of the leading figures in the field of global Biopharmaceutics, Dr Shi Wan, with constructive international experience and perspective, provides suggestions for the development of Shanghai at all stages "Every time I come to Shanghai to attend the conference, I can feel the changes of the city, from the rapid development of the city to the open and pragmatic work style of the government, which has left me a deep impression," said Dr Shi Wan of this special Shanghai sentiment "We have not only experienced the changes of Shanghai's reform and opening up, but also participated in the construction of China's biomedical industry." 。 Roche will make full use of its international experience and expertise in the field of biotechnology and work with the Shanghai municipal government to make sustained contributions to deepening Shanghai's urban brand " In the 24 years of HUAFA exhibition, Roche has invested heavily in R & D and innovation As one of the first batch of multinational pharmaceutical enterprises settled in Zhangjiang High Tech Park, Roche pharmaceutical has established a complete pharmaceutical value chain including drug research, development, production and marketing ahead of China, and has fulfilled its commitment of "based on China and serving China" with practical actions In 2015, Roche headquarters added 863 million yuan of investment to build Roche innovation center in Zhangjiang, aiming to make Shanghai the third largest strategic center in the world after Basel and San Francisco The center, which is expected to be completed in 2019, will focus on early research and drug development in the fields of immunity, inflammation and anti infection, and constantly meet the needs of patients in China and the world In recent years, with the deepening of reform and opening up, the Chinese government has launched a series of new measures for medical reform, especially in accelerating the process of new drug registration and approval, updating the national medical insurance catalog and so on At present, Roche has five targeted drugs - Herceptin ®, avidin ®, rituximab ®, trocaine ®, zobov ®, which are listed in the national health insurance catalog, benefiting more Chinese patients In August this year, Roche's new lung cancer drug, ansanza ® (alatinib), was approved by the State Drug Administration only nine months after it was approved in Europe and the United States It basically achieved synchronization with Europe and the United States 46 days after it was approved, it issued the first batch of prescriptions in China, which was closely linked and witnessed the speed of China These achievements demonstrate the confidence and determination of the Chinese government in improving the quality of medical services To this end, Ms Zhou Hong, general manager of Shanghai Roche Pharmaceutical Co., Ltd., said: "as a global leader in biotechnology and individualized medical treatment, Roche has always been adhering to the concept of" taking the needs of patients first "to help patients extend their lives and improve their lives Rooted in China for more than 20 years, thanks to the full support of governments at all levels, I believe that more Chinese patients will use innovative drugs as soon as possible in the future " At present, Roche pharmaceutical has 18 products in China, covering 8 treatment fields It is a market leader in key fields such as anti-tumor, anti-virus and transplantation Shanghai has made remarkable achievements in reform and opening up, continuously optimized its business environment and improved its government service level, and launched a series of national strategies such as vigorously promoting the construction of a science and technology innovation center with global influence and Zhangjiang National Science City These measures have greatly stimulated the vitality of enterprises, and also ushered in unprecedented new opportunities for innovative multinational enterprises represented by Roche At the beginning of November this year, Shanghai will usher in the first China International Import Expo, which has created a new platform for inclusive and open cooperation for domestic and foreign enterprises At that time, Roche will comprehensively demonstrate the cutting-edge technology in early research and development, the concept of "integration of diagnosis and treatment" covering the whole life cycle, and the innovative solutions of individualized medical treatment, and build an Asian Medical Center City, while continuously promoting the rapid development of China's medical industry.